ArticleOncotarget2017
Lenalidomide overcomes the immunosuppression of regulatory CD8
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.Cell reports. Medicine · 2024Article
- Lenalidomide use in multiple myeloma (Review).Molecular and clinical oncology · 2024Review
- Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy.Journal of personalized medicine · 2021Review
- Selective elimination of immunosuppressive T cells in patients with multiple myeloma.Leukemia · 2021Article
- Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma.Cancers · 2021Review
- Developing next generation immunomodulatory drugs and their combinations in multiple myeloma.Oncotarget · 2021Article
- Aging-associated immune system changes in multiple myeloma: The dark side of the moon.Cancer treatment and research communications · 2021Review
- Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.Leukemia · 2021Article
- The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.Frontiers in immunology · 2020Review
- Mechanisms of failure of chimeric antigen receptor T-cell therapy.Current opinion in hematology · 2019Review
- Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.Blood cancer journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although lenalidomide and pomalidomide are well-established treatment options in patients with multiple myeloma, their immune-modulating effects are not fully understood. While CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.